Page 1 | Search Results | Hematology, ASH Education Program

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Genomics of aggressive B-cell lymphoma

Allison Rosenthal, Lisa Rimsza

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 69–74.

https://doi.org/10.1182/asheducation-2018.1.69

Published: 2018

Journal Articles

Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?

Andrew Davies

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 284–294.

https://doi.org/10.1182/asheducation-2017.1.284

Published: 2017

Journal Articles

Current treatment of double hit and double expressor lymphoma

Patrick M. Reagan, Andrew Davies

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 295–297.

https://doi.org/10.1182/asheducation-2017.1.295

Published: 2017

Journal Articles

The role of targeted therapy in the management of patients with AML

Alexander E. Perl

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 54–65.

https://doi.org/10.1182/asheducation-2017.1.54

Published: 2017

Journal Articles

Diffuse large B-cell lymphoma: R-CHOP failure—what to do?

Bertrand Coiffier, Clémentine Sarkozy

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 366–378.

https://doi.org/10.1182/asheducation-2016.1.366

Published: 2016

Journal Articles

Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC

Steven H. Swerdlow

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 90–99.

https://doi.org/10.1182/asheducation-2014.1.90

Published: 2014

Journal Articles

Impact of MYC on malignant behavior

German Ott

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 100–106.

https://doi.org/10.1182/asheducation-2014.1.100

Published: 2014

Journal Articles

Double-hit lymphomas: current paradigms and novel treatment approaches

Kieron Dunleavy

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 107–112.

https://doi.org/10.1182/asheducation-2014.1.107

Published: 2014

Journal Articles

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1 , SF3B1 , and TP53

Clive S. Zent, W. Richard Burack

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 119–124.

https://doi.org/10.1182/asheducation-2014.1.119

Published: 2014

Journal Articles

Understanding MYC -driven aggressive B-cell lymphomas: pathogenesis and classification

German Ott, Andreas Rosenwald, Elias Campo

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 575–583.

https://doi.org/10.1182/asheducation-2013.1.575

Published: 2013

Journal Articles

Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma

Laurie H. Sehn

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 402–409.

https://doi.org/10.1182/asheducation.V2012.1.402.3798516

Published: 2012

Journal Articles

B Cells Behaving Badly: A Better Basis to Behold Belligerence in B-Cell Lymphomas

Adam Bagg

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 330–335.

https://doi.org/10.1182/asheducation-2011.1.330

Published: 2011

Journal Articles

Aggressive B-Cell Lymphomas: A Review of New and Old Entities in the WHO Classification

Elaine S. Jaffe, Stefania Pittaluga

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 506–514.

https://doi.org/10.1182/asheducation-2011.1.506

Published: 2011

Journal Articles

Novel Insights into the Biology of CLL

Mark C. Lanasa

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 70–76.

https://doi.org/10.1182/asheducation-2010.1.70

Published: 2010

Journal Articles

Rational Approaches to Design of Therapeutics Targeting Molecular Markers

Richard J. Klasa, Alan F. List, Bruce D. Cheson

Hematology Am Soc Hematol Educ Program (2001) 2001 (1): 443–462.

https://doi.org/10.1182/asheducation-2001.1.443

Published: 2001

NARROW

Genomics of aggressive B-cell lymphoma

Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?

Current treatment of double hit and double expressor lymphoma

The role of targeted therapy in the management of patients with AML

Diffuse large B-cell lymphoma: R-CHOP failure—what to do?

Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC

Impact of MYC on malignant behavior

Double-hit lymphomas: current paradigms and novel treatment approaches

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1 , SF3B1 , and TP53

Understanding MYC -driven aggressive B-cell lymphomas: pathogenesis and classification

Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma

B Cells Behaving Badly: A Better Basis to Behold Belligerence in B-Cell Lymphomas

Aggressive B-Cell Lymphomas: A Review of New and Old Entities in the WHO Classification

Novel Insights into the Biology of CLL

Rational Approaches to Design of Therapeutics Targeting Molecular Markers

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only